可孚医疗科技股份有限公司 2025 年半年度报告全文 可孚医疗科技股份有限公司 2025 年半年度报告 2025-059 2025 年 8 月 1 可孚医疗科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人张敏、主管会计工作负责人陈望朋及会计机构负责人(会计主 管人员)申佩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来计划、发展战略等前瞻性陈述的内容，均不构成公 司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十 公司面临的风险和应 对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投 资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以实施 2025 年半年度权 益分派时股权登记日登记的总股本扣除公司回购专用证券账 ...

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - The report indicates that the destocking phase for live pigs is nearing its end, with a focus on the effects of a new round of pork reserves [1] - The report highlights a recent decline in pork prices, with the average price for live pigs at 13.75 yuan/kg, down 0.07% week-on-week, and a significant drop in the price of piglets by 3.78% to 27.78 yuan/kg [1][22] - The report notes an increase in the average weight of slaughtered pigs, which is expected to stabilize prices as the government resumes pork reserves to boost market sentiment [1][22] Summary by Sections 1. Market Overview - The agriculture, forestry, animal husbandry, and fishery sector underperformed compared to the broader market, with the sector index rising by 3.72% while the Shanghai Composite Index rose by 3.49% [13] - The report provides a detailed performance breakdown of sub-sectors, with livestock farming showing a 4.31% increase [13] 2. Key Data Tracking 2.1 Live Pigs - The average weight of slaughtered pigs is reported at 127.98 kg, showing a slight increase of 0.16 kg week-on-week [22] - The national frozen meat storage capacity rate is at 14.77%, up 0.1 percentage points [22] 2.2 White Feather Broilers - The price of white feather broilers increased to 7.33 yuan/kg, up 1.81% week-on-week, while chick prices remained stable at 3.58 yuan each [31] 2.3 Yellow Feather Broilers - The price of medium-speed chickens rose to 6.34 yuan/jin, reflecting a 4.97% increase, driven by rising demand post-typhoon [40] 2.4 Feed Sector - The report notes a decline in the prices of corn, wheat, and soybean meal, with corn averaging 2373.53 yuan/ton, down 0.86% week-on-week [2][45] 2.5 Major Agricultural Products - The price of natural rubber fell to 15640 yuan/ton, down 0.89% week-on-week, with inventory levels decreasing slightly [60] 3. Investment Recommendations - The report recommends focusing on the pig farming sector, suggesting that the long-term profitability cycle is beginning to improve, with specific companies highlighted for investment: Muyuan Foods, Wens Foodstuff Group, Juxing Agriculture, and Shennong Group [3] - It also suggests monitoring the feed and animal health sectors, particularly companies like Haida Group and Ruipu Biological, as demand is expected to rise [3] - In the planting chain, the report identifies investment opportunities in companies such as Suqian Agricultural Development and Beidahuang Group due to favorable grain price trends [3]

Core Viewpoint - The stock of Kefu Medical (301087) has experienced a decline in price and significant net outflow of funds, indicating potential challenges in market sentiment and performance [1][2]. Group 1: Stock Performance - As of August 22, 2025, Kefu Medical's stock closed at 40.71 yuan, down 1.19% with a turnover rate of 2.05% and a trading volume of 39,900 hands, resulting in a transaction amount of 162 million yuan [1]. - Over the past five days, the stock has shown a consistent downward trend, with a total net outflow of main funds amounting to 4,563.78 million yuan and a net inflow from retail investors of 4,375.03 million yuan [2]. Group 2: Financial Metrics - Kefu Medical's total market capitalization is 8.512 billion yuan, with a net asset value of 4.909 billion yuan and a net profit of 914.251 million yuan [3]. - The company's price-to-earnings ratio (P/E) stands at 23.28, significantly lower than the industry average of 77.99, indicating a potentially undervalued stock [3]. - The gross margin is reported at 52.17%, slightly above the industry average of 51.31%, while the net profit margin is 12.41%, higher than the industry average of 10.85% [3]. Group 3: Recent Ratings and Target Price - In the last 90 days, one institution has given a rating of "buy" for Kefu Medical, with an average target price set at 45.0 yuan [4].

Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Market Position - As of August 22, Cofoe Medical's stock closed at 40.71 yuan, down 1.19%, with a rolling price-to-earnings (PE) ratio of 28.19 times, and a total market capitalization of 8.512 billion yuan [1]. - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Cofoe Medical at the 55th position within the industry [1][3]. Capital Flow - On August 22, the company experienced a net outflow of 21.48 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 21.12 million yuan [1].

Group 1 - The stock price of Kefu Medical is reported at 41.20 yuan as of August 21, 2025, with a decrease of 1.90% compared to the previous trading day and a trading volume of 1.31 billion yuan [1] - Kefu Medical operates in the medical device sector, focusing on product research and sales in health monitoring, rehabilitation aids, and medical care [2] - A recent policy document issued by the National Health Commission and other departments emphasizes the enhancement of ear disease prevention and rehabilitation services, which may benefit Kefu Medical as a related concept stock [2] Group 2 - On August 21, there was a net outflow of 6.993 million yuan in main funds, while the net inflow over the past five days was 65.7165 million yuan [3]

Group 1 - The agriculture and forestry sector experienced a short-term surge, with Kangnong Seed Industry rising over 10% [1] - Other companies such as Honghui Fruits and Vegetables, Qiule Seed Industry, Shennong Seed Industry, Quanyin High-Tech, and Nongfa Seed Industry also saw increases [1]

Core Viewpoint - The stock price of Kefu Medical closed at 42.00 yuan on August 20, 2025, reflecting a decline of 1.50% from the previous trading day [1] Company Overview - Kefu Medical specializes in the research, development, production, and sales of medical devices, with products spanning rehabilitation care, medical electronics, and consumables [1] - In the first quarter of 2025, the company reported a revenue of 738 million yuan and a net profit attributable to shareholders of 91.43 million yuan [1] Shareholder Activity - On August 20, 2025, Kefu Medical announced that its controlling shareholder, Changsha Medical Investment Co., Ltd., has released the pledge of 8.01 million shares, which accounts for 9.41% of its holdings and 3.83% of the company's total share capital [1] Capital Flow - On August 20, 2025, the net outflow of main funds was 5.0974 million yuan, while the cumulative net inflow of main funds over the past five trading days reached 119.7495 million yuan [1]

证券日报网讯 8月20日晚间，可孚医疗发布公告称，公司近日接到公司控股股东长沙械字号医疗投资有 限公司通知，获悉其所持有的本公司部分股份办理了解除质押业务，本次解除质押股份数量为8，010， 000股。 （编辑 姚尧） ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Cofoe Medical, indicating a decline in revenue and profit in the latest quarterly report while comparing its valuation metrics to industry averages [1][2][3] Group 2 - Cofoe Medical's stock closed at 42.0 yuan, down 1.50%, with a rolling PE ratio of 29.08 times and a total market capitalization of 8.782 billion yuan [1] - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, placing Cofoe Medical at the 56th position in the industry ranking [1][3] - As of the first quarter of 2025, five institutions held shares in Cofoe Medical, with a total of 6.344 million shares valued at 211 million yuan [1] - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical supplies [2] - The latest quarterly report for Q1 2025 shows Cofoe Medical achieved revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-056 可孚医疗科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）近日接到公司控股股东长 沙械字号医疗投资有限公司（以下简称"械字号投资"）通知，获悉其所持有的 本公司部分股份办理了解除质押业务，具体情况如下： 一、股东股份解除质押的基本情况 1、本次股份解除质押基本情况 | 股东名称 | 是否为控股股东 或第一大股东及 | 本次解除质押 | 占其所持 | 占公司总 | 起始日 | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一致行动人 | 股份数量（股） | 股份比例 | 股本比例 | | | | | | 械字号投资 | 是 | 8,010,000 | 9.41% | 3.83% | 2025年5月 | 2025 年 | 8 月 19 | 中国银行股份有限 公司湖南湘江新区 | | | | | ...